Kevin is the founder, Chief Executive Officer and Chairman of the board of Elixiron Immunotherapeutics. Over the course of his career, Kevin has been committed to advancing the development of breakthrough treatments with specific emphasis on translational medicine. Most recently, he served as Senior Vice President and Chief Medical Officer of Eusol Biotech Co., Ltd., a clinical stage company focused on developing therapeutic biologics for neurological diseases. Prior to Eusol, Kevin served as Director of Translational Medicine at Development Center for Biotechnology (DCB), Taiwan, where he led an initiative to implement translational medicine strategy across drug development stages. Kevin played a key role in strategic planning and building DCB’s immune-oncology portfolio, and led the development of preclinical candidates of anti-TIM3 and CSF1R inhibitor for cancer immunotherapy. Prior to DCB, Kevin was Principal Scientist at GlaxoSmithKline’s Neuroimmunology Discovery Performance Unit in Shanghai. There, he led an integrated project team and successfully moved a novel drug discovery project from target identification/validation, high throughput screen, to lead optimization. Kevin also served on global development teams, leading the biomarker and translational studies for a Ph2 clinical trial. Prior to joining GSK, Kevin served as Assistant Investigator at Translational Research Center of Gladstone Institutes, San Francisco. He actively participated in a multi-million dollar academia-industry collaborative project with Merck & Co., Inc. for the development of small molecule drugs for treating Alzheimer’s disease. Kevin earned his M.D. and Ph.D. from National Yang-Ming University and completed postdoctoral training at Baylor College of Medicine and Howard Hughes Medical Institute at Houston, Texas. Kevin has authored or co-authored several peer-reviewed manuscripts in the leading’s journals including Cell, Nature Medicine and Nature Communications.